Previous 10 | Next 10 |
home / stock / trypf / trypf news
KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today a...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has expanded its leadership team with the appointment of Jim O’Neill as its chief fina...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced that it has retained IMS Investor Relations. According to the announcement, IMS will work with Tryp Therape...
KELOWNA, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today a...
TRYP THERAPEUTICS INC. ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT Canada NewsWire SAN DIEGO , July 8, 2022 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company foc...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of a new provisional patent for the use of psilocybin for the treatment of patients with b...
Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment Canada NewsWire Biotech Company Strengthens Strategic Intellectual Property Protection of Targeted Indication SAN DIEGO , June 29, 2022 ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that Sid Taubenfeld, a seasoned executive with health care and biotech expertise, has joined the comp...
Tryp Therapeutics ( OTCQB:TRYPF ) has announced that Sid Taubenfeld , a seasoned executive with healthcare and biotech expertise, has joined the Co.'s senior leadership team as Chief Operating Officer. "Sid brings to his new role a wealth of expertise in building and growing e...
Tryp Therapeutics Appoints New Chief Operating Officer Canada NewsWire Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments SAN ...
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc Com Company Name:
TRYPF Stock Symbol:
OTCMKTS Market:
Tryp Therapeutics Inc Com Website:
Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) (" Tryp " or the " Company ") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the " Financial Statements "), along with the corresponding Manage...
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...